Frost & Sullivan Predicts Growth for the Infectious Disease Diagnostics Market
Point-of-care and molecular testing will be the highest growth segments in the infectious disease testing market
The infectious disease diagnostics market is driven by unprecedented outbreaks of infections and rising awareness of people and policy makers towards the vital use of diagnostic tools to control widespread outbreaks.
In developed markets, infectious disease testing is moving towards the patients’ bedside and the physicians’ office laboratories (POL). This is expected to be a growing trend, where the first round of testing will be done in the POL and samples will be sent to the central laboratories for confirmatory testing alone.
New analysis from Frost & Sullivan, Western European Infectious Disease Testing Market, finds that the market earned revenues of $74.1 million for MRSA segment, $13.2 million for TB segment, $42.1 million for HPV segment and $3.9 million for hantavirus Infections in 2011.
“The point-of-care and molecular testing segments are the highest growth segments in the infectious disease testing market,” notes Frost & Sullivan Research Analyst Tridisha Goswami. “In addition, as miniaturization has become a growing trend in the infectious disease testing market, it is important for companies to establish strong partnerships with manufacturing leviathans, typically found in China and India.”
On the other hand, restraints of this market include lack of awareness of the specific symptoms and diagnosis of emerging infections, as well as the stringent government regulations, which constitute barriers for new competitors and control price rise.
“Cost and time intensiveness of research & development represents a restraint for small companies in a market dominated by a few big market participants, which further hinders smaller companies from entering the market itself,” adds Goswami.
Molecular testing for infectious diseases is expected to be the preferred mode of testing and is likely to completely replace culture-based testing over the next 10 years, as cheaper tests become available to cater to higher testing volumes and investing in R&D for the same would reap benefits for market players.
“In the future, it is expected that multiplex testing panels of hundreds of diseases will be available and capable to screen for several strains as well as emerging infections at the same time. As technologies are also changing, market players will have to work along these changes to achieve higher growth and profits,” concludes Goswami.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
